Sinovac (SVA) Reports Unaudited 2009 Q3 Financial Results
November 16, 2009 6:34 AM
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced its unaudited financial results for the three-month and nine-month periods ended September 30, 2009.
Sales for the third quarter increased 142% to $21.2M,Sales for the nine-month period increased 40% to $47.8M,Operating income for the third quarter rose 436% to $12.4M,Operating income for the nine-month period increased 90% to $23.7M,Net income ttributable to the shareholders increased 606% to $5.2M in the third quarter, with diluted EPS of $0.12 .Cash and cash equivalents at September 30, 2009 was $46.6M.
Sinovac (SVA) is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases.
